BNGONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Bionano Genomics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$1.22−0.03 (-2.40%)
Close on Oct 19, 2026
- Market cap
- $14.09M
- P/E (TTM)
- –
- Dividend yield
- –
Bionano Genomics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $26.74M | $27.01M | $26.73M | $20.43M | $12.69M | $6.23M | $9.47M | $11.46M | $8.77M | 93.8% | -1.0% |
| Consumables | $13.97M | $12.77M | $11.16M | $6.73M | $5.81M | $3.15M | $2.71M | $3.02M | – | 49.0% | +9.4% |
| Software | $6.41M | $6.19M | $5.57M | $5.13M | $991.00K | – | – | – | – | 22.5% | +3.5% |
| Instruments | $6.36M | $8.04M | $10.00M | $8.57M | $5.89M | $3.09M | $6.76M | $8.44M | – | 22.3% | -20.9% |
| Services and other | $1.77M | $3.77M | $9.39M | $7.38M | $5.30M | $2.27M | $655.06K | $537.56K | $735.34K | 6.2% | -53.2% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EMEA | $14.11M | $14.23M | $12.96M | $8.96M | $5.60M | $3.16M | $3.63M | $3.95M | $1.28M | 49.5% | -0.9% |
| Americas | $12.18M | $13.65M | $18.02M | $13.86M | $9.33M | – | – | – | – | 42.7% | -10.8% |
| Asia Pacific | $2.22M | $2.89M | $5.13M | $4.98M | $3.05M | $851.00K | $1.47M | $3.45M | $4.42M | 7.8% | -23.3% |
| Americas | – | – | – | – | $9.33M | $4.49M | $5.03M | $4.59M | $3.80M | – | – |
From the segment and revenue-disaggregation notes of Bionano Genomics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.